Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Escitalopram
Drug ID BADD_D00809
Description Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class.[A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
Indications and Usage Labeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients.
Marketing Status Prescription
ATC Code N06AB10
DrugBank ID DB01175
KEGG ID D07913
MeSH ID D000089983
PubChem ID 146570
TTD Drug ID D08RBC
NDC Product Code 68071-2051; 68071-2035; 51655-284; 68071-4984; 68071-5248; 70518-2472; 65162-705; 42708-023; 70518-1110; 0456-2010; 63187-281; 71610-425; 61919-652; 63187-217; 50090-3331; 16729-168; 55700-847; 69097-849; 45865-699; 76282-249; 71335-1002; 0456-2005; 43547-281; 67296-1421; 0615-8349; 68001-455; 70518-2597; 63629-8241; 70518-3151; 68071-4985; 67296-1200; 33342-053; 51655-449; 53002-1438; 70934-112; 70771-1146; 68788-7510; 68788-7559; 16729-170; 0615-8348; 70518-1876; 70518-2317; 43063-661; 70518-2430; 71335-1307; 43547-282; 50090-4915; 70771-1147; 55700-818; 0615-8366; 68001-456; 71335-1571; 16729-169; 69097-848; 71335-1187; 70518-1805; 70518-1785; 67296-1689; 68645-520; 60760-393; 53002-2438; 50090-4363; 76282-251; 71205-344; 71335-1241; 50090-1930; 60760-170; 0615-8365; 68788-7461; 42708-022; 72789-194; 54838-551; 76282-250; 68788-7912; 0456-2020; 69097-847; 68001-454; 68645-519; 50090-5312; 67296-1597; 71205-325; 53002-1453; 43547-280; 71335-1030; 0615-8350; 68071-3069; 50090-2196; 67296-1408; 71610-534; 70771-1145; 71335-2058
Synonyms Escitalopram | Escitalopram Oxalate | Lexapro
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 128196-01-0
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Congenital nose malformation03.16.04.001; 22.10.02.0030.000142%Not Available
Foaming at mouth07.05.05.019; 08.01.03.070; 17.02.05.0560.000095%Not Available
Ectopic kidney03.06.01.009; 20.01.06.0060.000142%Not Available
Atrioventricular septal defect02.04.02.029; 03.07.02.0050.000074%Not Available
Persistent left superior vena cava03.07.04.003; 24.03.03.0380.000095%Not Available
Tachyphrenia17.03.03.007; 19.10.03.0100.000190%Not Available
Hypoplastic right heart syndrome02.08.01.008; 03.07.11.0020.000142%Not Available
Left ventricle outflow tract obstruction02.08.01.009; 03.07.10.003; 24.03.03.0350.000025%Not Available
Right atrial dilatation02.04.02.0320.000095%Not Available
Abdominal wall haematoma07.16.05.005; 24.07.02.0390.000237%Not Available
Right aortic arch03.07.08.008; 24.03.03.0390.000025%Not Available
Pancreatic neuroendocrine tumour05.08.01.014; 07.21.09.009; 16.24.02.0050.000095%Not Available
Quality of life decreased13.18.01.0130.000095%Not Available
Congenital tricuspid valve incompetence02.07.05.003; 03.07.05.0120.000142%Not Available
Decreased eye contact17.02.05.055; 19.01.02.0120.000190%Not Available
Motor developmental delay17.01.02.023; 19.22.01.0050.000142%Not Available
Distributive shock24.06.02.0220.000190%Not Available
Respiratory muscle weakness15.05.06.003; 17.05.03.017; 22.09.01.0040.000095%Not Available
Seizure like phenomena17.12.03.0300.000095%Not Available
Psychological trauma19.01.02.0170.000095%Not Available
Stiff person syndrome10.04.10.017; 15.05.04.021; 17.05.02.0180.000285%Not Available
Invasive ductal breast carcinoma16.10.01.013; 21.05.01.0210.000142%Not Available
Lobular breast carcinoma in situ16.10.01.015; 21.05.01.0230.000237%Not Available
Decerebrate posture15.03.01.024; 17.02.05.0540.000095%Not Available
Infantile apnoea18.04.15.003; 22.11.02.0040.000380%Not Available
Selective eating disorder14.03.02.024; 19.09.01.0120.000237%Not Available
The 38th Page    First    Pre   38    Total 38 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene